Navigation Links
Avicena Reports Second Quarter 2007 Results
Date:8/31/2007

property portfolio, have broad applications in both pharmaceuticals and dermaceuticals. Avicena's pharmaceutical program centers on rare neurological disorders (orphan diseases). The company's pipeline includes drugs for Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS) and Huntington's disease. Avicena's Parkinson's disease candidate, PD-02, is currently in Phase III testing with the National Institutes of Health in one of the largest Parkinson's disease trials ever conducted. AL-02, the company's ALS candidate, and HD-02, its treatment for Huntington's disease, are soon expected to enter Phase III testing. Unlike traditional biotechnology companies, government and non-profit organizations largely fund Avicena's clinical programs. Avicena presently derives revenue from the sale of proprietary dermaceutical ingredients to skin care manufacturers.

SAFE HARBOR

This release contains forward-looking statements that reflect, among other things, management's current expectations, plans and strategies, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict. See "Risk Factors" under "Item 6. Management's Discussion and Analysis of Financial Condition and Results of Operation" from our Annual Report on Form 10-KSB for the year ended December 31, 2006, and other descriptions in the company's public filings with the Securities and Exchange Commission for a discussion of such risks, including the company's need for additional funds, the company's dependence on a limited number of therapeutic compounds, the stage of the products the company is developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, the company's ability to avoid infringement of the patent rights of others, and
'/>"/>

SOURCE Avicena Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , ... July 27, 2015 , ... Production of high ... the past few years in the EU. For instance, it surpassed the EUR 106 ... 92 million mark in 2010. Germany is a major producer, while Italy is a ...
(Date:7/27/2015)... Research presented at the 2015 AACC Annual ... studies that led to a fingerprick Ebola test becoming ... to receive approval from the World Health Organization (WHO). ... on West Africa by identifying ... to isolate and treat these patients much faster than ...
(Date:7/27/2015)... 27, 2015 The Brain & ... of its annual Klerman and Freedman Prizes, recognizing ... have been supported by NARSAD Young Investigator Grants. ... innovative ideas in neurobiological and psychosocial research, garner ... the early detection, treatment, prevention and cure of ...
(Date:7/27/2015)... ... ... Visual Assay was named as a finalist for the 53rd Annual R&D ... of the past year. More than 70 judges selected the finalists, including Visual ... at the 2015 R&D 100 Awards Dinner on November 13 at Caesars Palace in ...
Breaking Biology Technology:High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 4Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 5Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 6Visual Assay® Named Finalist in 53rd Annual R&D 100 Awards 2
... CITY, Aug. 4 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: ... in oncology and endocrinology, will announce its second quarter 2010 financial and ... The Company will host a conference call and webcast to discuss these ... , , , ...
... , Aug. 3 Ampio Pharmaceuticals, Inc. (OTC Bulletin ... the title of its press release on July 27 , ... in the body of the press release, Ampio has completed the ... DMI BioSciences. Ampio will file a Form 8-K with the SEC ...
... VIEJO, Calif. , Aug. 3 AVANIR ... that the Company will present at the 30th Annual Canaccord Genuity Growth ... time ( 2:00 p.m. Pacific time ) at the InterContinental Hotel ... with the opportunity to present to institutional investors and industry leaders.   ...
Cached Biology Technology:CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc. 2AVANIR to Present at the Canaccord Genuity Growth Conference 2
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
(Date:7/7/2015)... 7, 2015  Based on its recent analysis ... recognizes Credence ID, LLC with the 2015 Asia-Pacific ... the Year Award. Credence ID has developed a ... mission of offering enrollment and identification solutions to ... ID was formed by experts from the mobile ...
(Date:6/30/2015)... 2015 To bolster its efforts and commitment to ... today the addition of two new team members. ... and David Raviv will act as head of ... commitment to providing the most secure solutions for the enterprise ... Layer 7 Technologies, a provider of security and management products, ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... German Research Foundation) is setting up six additional Research ... This decision was taken by the DFG,s Senate at ... annual plenary meeting in Berlin. The new networks are ... current and urgent issues in their fields and to ...
... To trap and hold tiny microparticles, engineers at Harvard ... resonator to confine particles stably for up to several minutes. ... Nano Letters , could one day lead to the ... all-optical chips. "We demonstrated the power of what we ...
... researchers are the first to identify a stress hormone ... as a model to understand the evolution of the ... animals with backbones, including humans. While scientists have learned ... most modern animals, little was known about the hormones, ...
Cached Biology News:6 new research units established 26 new research units established 3By 'putting a ring on it,' microparticles can be captured 2MSU sea lamprey research sheds light on how stress hormones evolved 2
... depth • Reusable, press-to-seal gasket and cover ... and disassembled for hybridizing and imaging thick ... with up to a 13 mm diameter. ... Minimize specimen handling, eliminate evaporation and leaking ...
Comp Dim: chamber diam. depth 20 2.8 mm chamber maximum volume 720 μL...
...
... A direct, simple approach to ... well surface of an EIA ... maintains its integrity and availability ... dry, room temperature conditions ...
Biology Products: